CardioSource WorldNews | Page 27

Despite this paradox, diabetes is most certainly
a risk multiplier in atherosclerosis.

Despite this paradox, diabetes is most certainly a
risk multiplier in atherosclerosis. It increases the
risk of developing atherosclerosis and the incidence
of complications of atherosclerosis, and is associated with poorer outcomes from these events.
They noted that health care professionals have
the benefit of a wide variety of clinical trial data
supporting specific treatments and targets for

HELPING PATIENTS START AND STAY ON THERAPY
12 months of FREE§ Effient therapy with the $avings Card for
commercially insured patients
– This offer is invalid for cash-paying patients and those
whose prescription claims are eligible to be reimbursed,
in whole or in part, by any governmental program
§

Out-of-pocket cost for patient is free. Restrictions may apply.

Learn more at EffientHCP.com
Effient is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary
syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: [1] patients with unstable angina (UA) or
non–ST-elevation myocardial infarction (NSTEMI); [2] patients with ST-elevation myocardial infarction (STEMI) when managed with primary
or delayed PCI.
The loading dose (LD) of Effient is 60 mg and the maintenance dose (MD) is 10 mg once daily. Effient is available in 5-mg and 10-mg tablets.

IMPORTANT SAFETY INFORMATION
WARNING: BLEEDING RISK
Effient® (prasugrel) can cause significant, sometimes fatal, bleeding.
Do not use Effient in patients with active pathological bleeding or a
history of transient ischemic attack or stroke.
In patients ≥75 years of age, Effient is generally not recommended,
because of the increased risk of fatal and intracranial bleeding
and uncertain benefit, except in high-risk situations (patients with
diabetes or a history of prior myocardial infarction [MI]) where its
effect appears to be greater and its use may be considered.
Do not start Effient in patients likely to undergo urgent coronary
artery bypass graft surgery (CABG). When possible, discontinue
Effient at least 7 days prior to any surgery.
Additional risk factors for bleeding include:
body weight <60 kg
propensity to bleed
concomitant use of medications that increase the risk of
bleeding (eg, warfarin, heparin, fibrinolytic therapy, chronic
use of nonsteroidal anti-inflammatory drugs [NSAIDs])
Suspect bleeding in any patient who is hypotensive and has recently
undergone coronary angiography, percutaneous coronary
intervention (PCI), CABG, or other surgical procedures in the
setting of Effient.
If possible, manage bleeding without discontinuing Effient.
Discontinuing Effient, particularly in the first few weeks after
acute coronary syndrome, increases the risk of subsequent
cardiovascular events.
Please see Brief Summary of Prescribing Information, including
Boxed Warning regarding bleeding risk, on subsequent pages.

CONTRAINDICATIONS
Effient is contraindicated in patients with active pathological
bleeding, such as from a peptic ulcer or intracranial hemorrhage
(ICH), or a history of transient ischemic attack (TIA) or stroke,
and in patients with hypersensitivity to prasugrel or any
component of the product

WARNINGS AND PRECAUTIONS
Patients who experience a stroke or TIA while on Effient
generally should have therapy discontinued. Effient should also
be discontinued for active bleeding and elective surgery
Premature discontinuation of Effient increases risk of stent
thrombosis, MI, and death
Thrombotic thrombocytopenic purpura (TTP), a rare but serious
condition that can be fatal, has been reported with Effient,
sometimes after a brief exposure (<2 weeks), and requires urgent
treatment, including plasmapheresis
Hypersensitivity, including angioedema, has been reported in
patients receiving Effient, including patients with a history of
hypersensitivity reaction to other thienopyridines

ADVERSE REACTIONS
Bleeding, including life-threatening and fatal bleeding, is the
most commonly reported adverse reaction
Represents commercial plans: HMO, PBM, POS, PPO, Employer, Insurer,
and Health Insurance Exchange (HIX) formulary data.
‡
Represents MA-PD and PDP formulary data.
Underlying enrollment values developed by Managed Markets Insight &
Technology (MMIT), LLC as of June 2015 using a combination of third-party
and public sources as well as a proprietary allocation methodology. The values
may not be representative of an individual physician’s patient population.
†

Effient and the Effient logo are registered trademarks of Eli Lilly and Company.
©Daiichi Sankyo, Inc. and Lilly USA, LLC 12/2015. All Rights Reserv